Insulin degludec: Overview of a novel ultra long-acting basal insulin

All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing. Insulin degludec is a novel acylated basal insulin with a unique mec...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Gough, S, Harris, S, Woo, V, Davies, M
التنسيق: Journal article
منشور في: 2013